Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study

Craig A. Hurwitz, Lewis C. Strauss, James Kepner, Cynthia Kretschmar, Michael B. Harris, Henry Friedman, Larry Kun, Richard Kadota

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose To assess the efficacy and define the toxicity of paclitaxel given at a dosage of 350 mg/m 2 every 3 weeks as a 24-hour continuous infusion to children with recurrent or progressive primary brain tumors. Patients and Methods Seventy-three eligible patients, ages 4 months to 19 years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330). Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15), ependymoma (n = 13), and miscellaneous histologies (n = 12). All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease. All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than one phase II trial. Paclitaxel was administered as a 24-hour intravenous infusion at a dosage of 350 mg/m 2 every 3 weeks. Neurologic and neuroradiologic reevaluations were performed after every second course. Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity. Results Seventy-five patients were enrolled onto the POG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy. Of the 73 eligible patients, 72 were evaluable for toxicity and 70 were either fully or partially evaluable for disease response. There was one complete response and three partial responses (5.7%). Twenty patients had stable disease for more than 2 months. Toxicities included mild nausea, central nervous system toxicity, myelosuppression, and febrile neutropenia, including one septic death. One grade 2 and two grade 3 allergic reactions occurred. No cardiac toxicities or arthralgias were reported. Conclusion Paclitaxel is well tolerated in children with recurrent or progressive brain tumors at this dosage and schedule and may result in short-term disease stabilization in this patient population. The lack of a significant number of patients with measurable disease regression, however, precludes it from being identified as an active agent when administered as a single agent by 24-hour continuous infusion.

Original languageEnglish (US)
Pages (from-to)277-281
Number of pages5
JournalAmerican Journal of Pediatric Hematology/Oncology
Volume23
Issue number5
StatePublished - Jan 1 2001

Fingerprint

Paclitaxel
Brain Neoplasms
Pediatrics
Therapeutics
Glioma
Spinal Cord Neoplasms
Ependymoma
Febrile Neutropenia
Medulloblastoma
Astrocytoma
Arthralgia
Intravenous Infusions
Documentation
Nausea
Nervous System
Brain Stem
Histology
Appointments and Schedules
Hypersensitivity
Radiotherapy

Keywords

  • Brain tumor
  • Paclitaxel
  • Pediatrics
  • Phase II

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Hurwitz, C. A., Strauss, L. C., Kepner, J., Kretschmar, C., Harris, M. B., Friedman, H., ... Kadota, R. (2001). Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study. American Journal of Pediatric Hematology/Oncology, 23(5), 277-281.

Paclitaxel for the treatment of progressive or recurrent childhood brain tumors : A pediatric oncology phase II study. / Hurwitz, Craig A.; Strauss, Lewis C.; Kepner, James; Kretschmar, Cynthia; Harris, Michael B.; Friedman, Henry; Kun, Larry; Kadota, Richard.

In: American Journal of Pediatric Hematology/Oncology, Vol. 23, No. 5, 01.01.2001, p. 277-281.

Research output: Contribution to journalArticle

Hurwitz, CA, Strauss, LC, Kepner, J, Kretschmar, C, Harris, MB, Friedman, H, Kun, L & Kadota, R 2001, 'Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study', American Journal of Pediatric Hematology/Oncology, vol. 23, no. 5, pp. 277-281.
Hurwitz, Craig A. ; Strauss, Lewis C. ; Kepner, James ; Kretschmar, Cynthia ; Harris, Michael B. ; Friedman, Henry ; Kun, Larry ; Kadota, Richard. / Paclitaxel for the treatment of progressive or recurrent childhood brain tumors : A pediatric oncology phase II study. In: American Journal of Pediatric Hematology/Oncology. 2001 ; Vol. 23, No. 5. pp. 277-281.
@article{d89e482d23c644cd975d50f6600ed345,
title = "Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study",
abstract = "Purpose To assess the efficacy and define the toxicity of paclitaxel given at a dosage of 350 mg/m 2 every 3 weeks as a 24-hour continuous infusion to children with recurrent or progressive primary brain tumors. Patients and Methods Seventy-three eligible patients, ages 4 months to 19 years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330). Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15), ependymoma (n = 13), and miscellaneous histologies (n = 12). All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease. All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than one phase II trial. Paclitaxel was administered as a 24-hour intravenous infusion at a dosage of 350 mg/m 2 every 3 weeks. Neurologic and neuroradiologic reevaluations were performed after every second course. Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity. Results Seventy-five patients were enrolled onto the POG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy. Of the 73 eligible patients, 72 were evaluable for toxicity and 70 were either fully or partially evaluable for disease response. There was one complete response and three partial responses (5.7{\%}). Twenty patients had stable disease for more than 2 months. Toxicities included mild nausea, central nervous system toxicity, myelosuppression, and febrile neutropenia, including one septic death. One grade 2 and two grade 3 allergic reactions occurred. No cardiac toxicities or arthralgias were reported. Conclusion Paclitaxel is well tolerated in children with recurrent or progressive brain tumors at this dosage and schedule and may result in short-term disease stabilization in this patient population. The lack of a significant number of patients with measurable disease regression, however, precludes it from being identified as an active agent when administered as a single agent by 24-hour continuous infusion.",
keywords = "Brain tumor, Paclitaxel, Pediatrics, Phase II",
author = "Hurwitz, {Craig A.} and Strauss, {Lewis C.} and James Kepner and Cynthia Kretschmar and Harris, {Michael B.} and Henry Friedman and Larry Kun and Richard Kadota",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "23",
pages = "277--281",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Paclitaxel for the treatment of progressive or recurrent childhood brain tumors

T2 - A pediatric oncology phase II study

AU - Hurwitz, Craig A.

AU - Strauss, Lewis C.

AU - Kepner, James

AU - Kretschmar, Cynthia

AU - Harris, Michael B.

AU - Friedman, Henry

AU - Kun, Larry

AU - Kadota, Richard

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose To assess the efficacy and define the toxicity of paclitaxel given at a dosage of 350 mg/m 2 every 3 weeks as a 24-hour continuous infusion to children with recurrent or progressive primary brain tumors. Patients and Methods Seventy-three eligible patients, ages 4 months to 19 years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330). Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15), ependymoma (n = 13), and miscellaneous histologies (n = 12). All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease. All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than one phase II trial. Paclitaxel was administered as a 24-hour intravenous infusion at a dosage of 350 mg/m 2 every 3 weeks. Neurologic and neuroradiologic reevaluations were performed after every second course. Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity. Results Seventy-five patients were enrolled onto the POG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy. Of the 73 eligible patients, 72 were evaluable for toxicity and 70 were either fully or partially evaluable for disease response. There was one complete response and three partial responses (5.7%). Twenty patients had stable disease for more than 2 months. Toxicities included mild nausea, central nervous system toxicity, myelosuppression, and febrile neutropenia, including one septic death. One grade 2 and two grade 3 allergic reactions occurred. No cardiac toxicities or arthralgias were reported. Conclusion Paclitaxel is well tolerated in children with recurrent or progressive brain tumors at this dosage and schedule and may result in short-term disease stabilization in this patient population. The lack of a significant number of patients with measurable disease regression, however, precludes it from being identified as an active agent when administered as a single agent by 24-hour continuous infusion.

AB - Purpose To assess the efficacy and define the toxicity of paclitaxel given at a dosage of 350 mg/m 2 every 3 weeks as a 24-hour continuous infusion to children with recurrent or progressive primary brain tumors. Patients and Methods Seventy-three eligible patients, ages 4 months to 19 years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330). Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15), ependymoma (n = 13), and miscellaneous histologies (n = 12). All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease. All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than one phase II trial. Paclitaxel was administered as a 24-hour intravenous infusion at a dosage of 350 mg/m 2 every 3 weeks. Neurologic and neuroradiologic reevaluations were performed after every second course. Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity. Results Seventy-five patients were enrolled onto the POG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy. Of the 73 eligible patients, 72 were evaluable for toxicity and 70 were either fully or partially evaluable for disease response. There was one complete response and three partial responses (5.7%). Twenty patients had stable disease for more than 2 months. Toxicities included mild nausea, central nervous system toxicity, myelosuppression, and febrile neutropenia, including one septic death. One grade 2 and two grade 3 allergic reactions occurred. No cardiac toxicities or arthralgias were reported. Conclusion Paclitaxel is well tolerated in children with recurrent or progressive brain tumors at this dosage and schedule and may result in short-term disease stabilization in this patient population. The lack of a significant number of patients with measurable disease regression, however, precludes it from being identified as an active agent when administered as a single agent by 24-hour continuous infusion.

KW - Brain tumor

KW - Paclitaxel

KW - Pediatrics

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=0034921207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034921207&partnerID=8YFLogxK

M3 - Article

C2 - 11464982

AN - SCOPUS:0034921207

VL - 23

SP - 277

EP - 281

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 5

ER -